Tests a treatment approach for certain muscle inflammation diseases
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Skin clinical trials.
This trial looks at treatment strategies for people with idiopathic inflammatory myopathies, which are illnesses where the immune system attacks muscles. It may help improve how treatment is chosen and optimized for this group of conditions, but it specifically excludes several related muscle diseases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an idiopathic inflammatory myopathy (immune-related muscle inflammation without a known cause).
- Your diagnosis must not be inclusion body myositis.
- Your diagnosis must not be a muscular dystrophy (genetic muscle-wear conditions).
- Your muscle condition must not be caused by a cancer-related problem.
- Your condition must not be an “overlap myopathy” (mixed immune muscle diseases).
- Your muscle condition must be classified as a type of myopathy that is included in this study (not one of the excluded types).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called nerandomilast in people with active inflammatory muscle disease (myositis) that is not well controlled with current treatments. It aims to see if the drug can improve muscle strength and overall disease activity.
This study follows people with inflammatory myositis over time to learn more about the condition. If you join, you may receive closer monitoring and contribute to research that could improve future treatments.
This study looks at adults who may have an autoimmune (self-immune) muscle disease. It aims to better understand and evaluate this condition, which may help guide future diagnosis and care.
This trial tests a new treatment called RD06-04, which uses your own immune cells modified to target a protein on faulty immune cells. It aims to reduce the autoimmune attack in two rare conditions and may help people who have not found relief from other treatments.
This trial is testing a new drug (a JAK inhibitor) for people with rare inflammatory diseases like Behçet's, myositis, or IgG4-related disease that hasn't improved with standard treatments. The goal is to see if it can help control symptoms and reduce inflammation.
This early-stage trial tests a new treatment called MTS109 for autoimmune diseases (like lupus, muscle inflammation, scleroderma, vasculitis, or Sjögren's syndrome) that haven't responded well to standard medications. The goal is to see if MTS109 can help control disease that keeps flaring or getting worse despite current treatments.
Hear when a new Idiopathic Inflammatory Myopathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.